DR2313产品活性：DR2313 是一种有效，选择性，竞争性的和可透过血脑屏障的 PARP 抑制剂，抑制 PARP-1 和 PARP-2 的 IC50 值分别为 0.20 μM 和 0.24 μM。DR2313 在体外和体内均表现出对缺血性损伤的神经保护作用。产品来源： https://www.medchemexpress.cn/dr2313.html研究领域：Cell Cycle/DNA Damage | Epigenetics作用靶点：作用靶点：PARPIn Vitro: DR2313 (0.016-16.4 μM; 30 min) inhibits poly(ADP-ribosyl)ation reaction in nuclear extracts of rat brain, with a Ki of 0.23 μM.DR2313 shows more powerful inhibition of the poly(ADP-ribosyl)ation in the nuclear extracts of the rat brain (IC50=0.20 μM) than 3AB (35.4 μM), PND (0.56 μM), DIQ (2.96 μM), and DPQ (0.96 μM).DR2313 (1-100 μM; 10 min) shows a weak inhibition of the mono(ADP-ribosyl)ation in a concentration-dependent manner (IC50=59 μM).DR2313 (0.1-30 μM; pretreated for 30 min) reduces hydrogen peroxide (500 μM; 4 h) or glutamate (1 mM; 30 min) induced excessive formation of poly(ADP-ribose) and cell death.In Vivo: DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats.相关产品：Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Anti-Aging Compound Library | Neuroprotective Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Olaparib | XAV-939 | Talazoparib | Niraparib | Veliparib | Rucaparib | AZD5305 | RBN-2397 | PJ34 | Pamiparib | Dehydrocorydaline | G007-LK | Fucosterol | 3-Aminobenzamide | RBN012759 | AG14361 | AZD-2461 | Fluzoparib | NVP-TNKS656 | NMS-P118 | Iniparib | AZ6102品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。https://www.medchemexpress.cn/dr2313.html